OUHSC Research News – Monday, December 5, 2022
Published: Friday, December 2, 2022
OUHSC Research News – Monday, December 5, 2022
Notices and Reminders
In alignment with the University’s closure for the upcoming holidays, the Office of the Vice President for Research (VPR) will be closed for:
Winter Break – The Office of the VPR including ORA will be closed on December 23, 2022 through January 2, 2023, reopening on January 3, 2023.
Any proposals or other items due to sponsors during this time must be submitted to ORA within three business days before the campus closure dates. Any contracts expiring December 30, 2022 need to be in our office by December 12, 2022. Should you need urgent assistance during the holiday closure, please contact ORA at HSCORA@ouhsc.edu. All other matters will be addressed when the University reopens for regular business hours.
Guidance for Collecting Demographic Diversity Data via Survey
In 2019 the National Institutes of Health (NIH) released the “Notice of NIH's Interest in Diversity” that identified populations that should be prioritized to ensure national scientific workforce diversity goals are achieved. To achieve this aim, identified offices on campus, including the Offices of Diversity, Equity, and Inclusion (DEI) and Institutional Research (IR), collaborate to understand the diversity attributes (ethnicity, disadvantaged status, disability status, etc.) of HSC faculty, staff, and students. These activities inform a number of functions including institutional planning, decision-making, and external reporting efforts. Reports on these data attributes are often included as a component of required annual reporting, as an example, or may be considered necessary in certain applications. In many cases, these data are available from the University already and need not be surveyed again. Prior to conducting your survey, please confirm with the DEI and IR offices to see if the data you need, or reliable proxy measures, are already available.
Survey Guidelines:
In cases where data collection is necessary, please adhere to the following guidelines to ensure your data collection activities result in valid, complete, and properly aggregated data:
- Include procedures to maintain the anonymity and confidentiality of survey respondents.
- Make clear to survey recipients that their participation is voluntary and they are free to not participate.
- Ensure that responses cannot be traced back to respondents.
- Ensure that no personally identifiable information is captured.
Exclusions:
- Survey instruments that are a component of an Institutional Review Board (IRB) approved research study don’t require further review.
If your survey instrument does not meet the exclusion criterion but you believe it needs to collect identifiable information, please contact the office of DEI at Diversity-Inclusion@ouhsc.edu.
You will be contacted to discuss your request and clarify the specific information you need. Please allow at least 3 business days for the completion of your request.
Workshops and Seminars
Save the Date! You are invited to …
“Navigating the World of Sponsored Research: An Overview” Workshop, offered jointly by the Office of Research Administration (ORA) and Grants & Contracts Accounting Office (GCA)
Date: January 26, 2023
Time: 8:00 am– 12:00 pm and 1:00 pm - 4:00 pm
Venue: Presbyterian Health Foundation (PHF) Conference Center, University Research Park, Building 655, Suite 100, Oklahoma City
Ever needed help with a grant submission?
Are budget questions keeping you from your real job?
Not quite sure how to support your faculty with their grants and contracts?
Finally, the moment you’ve been waiting for….
We are pleased to announce a joint workshop, “Navigating the World of Sponsored Research: An Overview” for faculty and staff. This workshop will offer a one-day training on sponsored research topics.
The National Symposium on Sexual Behavior of Youth Call for Poster Abstracts
Description: Join your colleagues on Wednesday, February 22, 2023 from 5:00p - 7:00p for the multi-disciplinary NSSBY poster session that will highlight the latest research, programs, and activities in the field. Light snacks will be available during the poster session, which will be concurrent with the Welcome Reception. The poster session provides opportunities for extended discussion with symposium participants about your work.
Poster submissions must be received by November 30, 2022. Announcements of acceptance will be made by December 15, 2022.
Posters describing innovative programs and implementation strategies are encouraged and welcomed. Posters can focus on a wide variety of topics related to the sexual behavior of youth, such as:
- sexual development
- sex education
- healthy sexual behavior
- impact of technology
- problematic/harmful and/or illegal sexual behavior
- assessment
- treatment
- long-term outcomes
More information can be found at: https://connect.ncsby.org/nssby2023/call-for-proposals/posters
Questions? OU-NCSBY@ouhsc.edu
OUHSC Funding Opportunities
Office of Technology Commercialization presents the following opportunity for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).
- Santen pharmaceuticals is seeking novel druggable targets and ocular drug delivery systems in ophthalmology. Druggable Targets and related patient biomarkers for the following diseases are of interest: presbyopia, myopia, Fuchs dystrophy, glaucoma, retinitis pigmentosa, dry eye disease, AMD, geographic atrophy and seasonal allergic conjunctivitis. Non-invasive and injectable drug delivery systems are of interest. Out of scope: therapeutic approaches to treat cataract, uveitis, wet AMD and ocular cancer; contact lens and punctal plug drug delivery systems. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 01/13).
- A world-leader in vaccine manufacturing is seeking research linking viral or bacterial infection and chronic disorders in order to develop new treatments targeting microbial pathogens. In scope: biological approaches to prevent or reduce chronic disease, research relating to any chronic condition, provided there is a validated link with bacterial or viral infection. Out of scope: small molecule, enzyme therapy, gene therapy and cell therapy. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 12/22).
American Cancer Society Institutional Research Grant (ACS-IRG)
DEADLINE: Friday, December 16, 2022; Due by 5:00 PM
ACS-IRG funds provide $50,000 to new/early stage faculty with cancer research pilot projects
Eligibility Criteria:
- ASSISTANT PROFESSOR or equivalent level position that holds a tenure- or research-track appointment on OUHSC, OU-Norman or OU-Tulsa campus and within SIX years of first independent academic appointment.
- Without CURRENT grant support from national funding agencies (e.g. NIH, DOD, NSF, ACS).
INSTRUCTIONS AND APPLICATION:
Application, Guidelines and more information can be found:
Application, Forms & Guidelines | SCC Website
For questions, please contact The SCC Office of Cancer Research
CancerResearch@ouhsc.edu
ASSISTANT PROFESSOR FACULTY POSITIONS: Cellular and Molecular GeroScience CoBRE
The Center for Geroscience and Healthy Brain Aging at the University of Oklahoma Health Sciences Center (OUHSC) invites exceptional scientists to apply for tenure-track eligible faculty positions. Applications from individuals with expertise in multiple research areas related to the biology of aging or to diseases associated with aging are requested. Areas of special interest include but are not limited to bioenergetics, metabolism, adult stem cells/tissue regeneration, cell signaling and mechanisms of neurodegeneration. The individual(s) selected will be appointed as Assistant Professor in a Basic Science Department at OUHSC and will join the NIA P20 Cellular and Molecular Geroscience CoBRE Program, from which they will receive substantial research funding while they apply for independent NIH funds. The start date will be during the Spring/Summer of 2023 at dates negotiated with successful applicants.
Minimum Qualifications and Requirements: Successful candidates are expected to develop innovative and externally funded research programs, participate in education programs, and contribute to university service. Candidates should have a PhD and/or MD and are expected to have significant postdoctoral research experience with the potential of developing a nationally recognized research program. The individuals should have Early Stage Investigator (ESI) status and not been awarded an independent NIH grant.
The Center for Geroscience and Healthy Brain Aging is a highly interactive group of scientists with interests in aging, brain aging, neurological diseases of aging, gero-oncology, developmental determinants of aging, metabolism, diabetes, and immunology. The Center for Geroscience is home to the NIA P30 Oklahoma Nathan Shock Center on Aging, the NIA T32 Geroscience Training Program and the NIA P20 Cellular and Molecular Geroscience CoBRE grant and receives over $10M in extramural funding annually. Successful applicants will receive a competitive salary, a multi-year start-up package, and be assigned newly renovated laboratory space.
Candidates should submit a Specific Aims page, an NIH Biosketch and a ½ page list of Future Directions as a single pdf file. Contact information for at least three references should be included. Please send the application packet to Melissa-K-Day@ouhsc.edu no later than Monday, December 12th, 2022. The applicant is expected to write a full CoBRE application that will be part of the Phase 2 CoBRE renewal due May 25, 2023, with the assistance of the leadership of the Center for Geroscience.
The University of Oklahoma and the Center for Geroscience have a commitment to diversity, equality, and inclusion. The University of Oklahoma Health Sciences Center is an equal employment opportunity and affirmative action institution http://www.ou.edu/eoo. Individuals with disabilities and protected veterans are encouraged to apply.
NIH Notices
NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
NIH Funding Opportunities
- Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)
(PAR-23-036)
Application Receipt Date(s): Multiple dates, see announcement.
- Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional)
(PAR-23-037)
Application Receipt Date(s): Multiple dates, see announcement.
- NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)
(PAR-23-057)
Application Receipt Date(s): January 07, 2026
- Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
(RFA-CA-23-002)
Application Receipt Date(s): Multiple dates, see announcement.
- Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
(RFA-CA-23-003)
Application Receipt Date(s): Multiple dates, see announcement.
- Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
(RFA-CA-23-004)
Application Receipt Date(s): Multiple dates, see announcement.
- Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
(RFA-CA-23-005)
Application Receipt Date(s): Multiple dates, see announcement.
- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
(RFA-CA-23-006)
Application Receipt Date(s): Not Applicable
- Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
(RFA-CA-23-007)
Application Receipt Date(s): Not Applicable
- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional)
(RFA-CA-23-008)
Application Receipt Date(s): Not Applicable
- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)
(RFA-CA-23-009)
Application Receipt Date(s): Not Applicable
- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
(RFA-CA-23-010)
Application Receipt Date(s): Not Applicable
- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)
(RFA-CA-23-011)
Application Receipt Date(s): Not Applicable
- NIDDK Information Network Coordinating Unit: dkNET-CU (U24 Clinical Trial Not Allowed)
(RFA-DK-22-017)
Application Receipt Date(s): March 31, 2023
- Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed)
(RFA-DK-22-027)
Application Receipt Date(s): Multiple dates, see announcement.
- Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01) Clinical Trial Optional
(RFA-FD-23-008)
Application Receipt Date(s): February 27, 2023
- Evaluation of Oral Modified Release Dosage Forms to Support the Approval of Additional Strengths (U01) Clinical Trial Not Allowed
(RFA-FD-23-013)
Application Receipt Date(s): March 15, 2023
- Designing and Performing a Virtual Bioequivalence Trial for Physiologically-Based Pharmacokinetic and other Mechanism-Based Models (U01) Clinical Trial Not Allowed
(RFA-FD-23-016)
Application Receipt Date(s): February 15, 2023
- Population Pharmacokinetic Modeling of Systemic Pharmacokinetic Data to Inform Bioequivalence in Regional Lung Exposure (U01) Clinical Trial Not Allowed
(RFA-FD-23-017)
Application Receipt Date(s): February 28, 2023
- Cooperative Agreement to Support Regulatory Research Related to the 2022 Prescription Drug User Fee Act and Biosimilar User Fee Act (U19) Clinical Trials Not Allowed.
(RFA-FD-23-023)
Application Receipt Date(s): March 13, 2023
- Opportunities for Advancing Limb Regeneration Research (R01 Clinical Trial Not Allowed)
(RFA-HD-24-004)
Application Receipt Date(s): July 27, 2023
- NIH Research Evaluation and Commercialization Hubs (REACH) Awards (U01 Clinical Trial Optional)
(RFA-OD-23-002)
Application Receipt Date(s): February 09, 2023
Other Funding Opportunities
The Leona M. and Harry B. Helmsley Charitable Trust
Description: Helmsley T1D Program seeks to fund studies that lead to solutions that improve management of exercise with T1D in the real world. The goal of the projects should be learning from the T1-DEXI data to provide people with T1D and healthcare providers practical management solutions for T1D and exercise and to improve clinical guidelines in a way that can be applied in the real world. All potential projects are expected to include a study component involving people with T1D.
Concept Notes Due: April 30, 2023
Full Grant Proposals Due (selected applicants): July 31, 2023
Link to Full Announcement: https://helmsleytrust.org/request_for_proposal/improving-exercise-with-type-1-diabetes-moving-data-towards-solutions/
2023 GCRLE Grants Call for Applications
The Global Consortium for Reproductive Longevity and Equality (GCRLE) is soliciting 2-year grant applications aimed at identifying unifying principles that underlie female reproductive aging. Our goal is to facilitate ambitious projects and stimulate collaborations across disciplines that will help define the field of female reproductive longevity and empower women with parity and options in their reproductive choices. The awards are open to researchers based at both national and international accredited academic and nonprofit research institutions. We would greatly appreciate it if you could share this announcement with anyone you know who might be qualified or to your institution’s relevant grant officer. Details can be found on the application page when the application portal opens on November 18th, 2022.
Applications Due: The deadline to apply for this award is December 16th, 2022 at 11:59pm PST. All materials required will be found on the application portal at gcrle.org/apply when it opens.
The application process is designed to be straightforward with a simple 2-page proposal.
Specific Funding Mechanisms (2-year awards)
- Senior Scholar Awards fund established investigators who are thought leaders in their respective fields and are recognized for substantial contributions of creative and productive research to pursue substantive, innovative research in female reproductive aging. This award grants $400,000/year in funding.
- Junior Scholar Awards fund early career investigators with outstanding promise when they are establishing their own labs. These awards are to encourage young scientists to pursue bold ideas in female reproductive aging when they are at their most scientifically creative. This award grants $250,000/year in funding.
- Postdoctoral Fellowship Awards fund exceptional young scientists at the beginning of their postdoctoral training in the area of female reproductive aging, broadly defined. Our goal is to provide support and training to promising postdoctoral scholars and to encourage the next generation of researchers to pursue creative projects in this exciting, nascent field. This award grants $100,000/year in funding, $70,000 of which must be used for the Fellow’s salary.
- Pilot Awards fund pilot projects to foster innovative or novel research projects in female reproductive aging that have the potential for high impact and high reward at an accelerated rate. This award grants $100,000/year in funding.
For all funding mechanisms, we seek to complement other major funders of research by placing emphasis on projects that may not be supported by traditional sources because of their perceived novelty or high risk, or because the investigator is moving into female reproductive aging from a different research area. We look forward to your applications!
Cystic Fibrosis Foundation Call for Mental Health Research Working Group Members
Description: The mission of the Cystic Fibrosis Mental Health Research Working Group (MHRWG) is to advance our knowledge of mental health conditions in the CF population throughout the lifespan and promote clinical and translational research that will improve the understanding, prevention, diagnosis, and treatment of mental health concerns in CF. The MHRWG is seeking to create a multi-disciplinary group, including, but not limited to, physicians/psychiatrists, psychologists/neuropsychologists, social workers, pharmacists etc., and other specialists with an interest in CF mental health. Applications must be submitted online at awards.cff.org. For questions, please contact Dara Riva (driva@cff.org) and Kayli Davis (kaydavis@cff.org).
Applications Due: December 14, 2022
Link to Full Announcement: https://www.cff.org/researchers/mental-health-research-working-group
The Leona M. and Harry B. Helmsley Charitable Trust’s (Helmsley) Type 1 Diabetes (T1D) Program
Description: The Leona M. and Harry B. Helmsley Charitable Trust’s (Helmsley) Type 1 Diabetes (T1D) Program is launching a Request for Proposals (RFP) to support the development of novel, real-world solutions to help people with T1D exercise safely and to improve their quality of life. Researchers and clinicians are expected to partner with statistical teams to analyze the real-world data that was collected under Helmsley’s T1D Exercise Initiative (T1-DEXI), build collaborations with other necessary third parties, and to test their novel solutions in studies with people with T1D. The overarching purpose of this initiative is to move real-world data towards real-world solutions.
Concept Notes due: April 30, 2023
Link to Full Announcement: https://helmsleytrust.org/request_for_proposal/improving-exercise-with-type-1-diabetes-moving-data-towards-solutions/
Cystic Fibrosis Foundation Idea Development Award
Description: The Spring 2023 Idea Development Award (IDA) is intended to support work that leads to sufficient project development to enable an application for future research funding from the Cystic Fibrosis Foundation or the National Institutes of Health. For more information, visit the IDA webpage. For questions, please contact Dara Riva (driva@cff.org).
Applications Due: February 2, 2023
Link to Full Announcement: https://www.cff.org/researchers/idea-development-award